caa a22 4500 606158022 CHVBK 20210128100617.0 cr unu---uuuuu 210128e20151101xx s 000 0 eng 10.1007/s10096-015-2472-0 doi (NATIONALLICENCE)springer-10.1007/s10096-015-2472-0 Economic assessment of fidaxomicin for the treatment of Clostridium difficile infection (CDI) in special populations (patients with cancer, concomitant antibiotic treatment or renal impairment) in Spain [Elektronische Daten] [C. Rubio-Terrés, J. Cobo Reinoso, S. Grau Cerrato, J. Mensa Pueyo, M. Salavert Lletí, A. Toledo, P. Anguita, D. Rubio-Rodríguez, M. Watt, R. Gani] The objective of this paper was to assess the cost-utility of fidaxomicin versus vancomycin in the treatment of Clostridium difficile infection (CDI) in three specific CDI patient subgroups: those with cancer, treated with concomitant antibiotic therapy or with renal impairment. A Markov model with six health states was developed to assess the cost-utility of fidaxomicin versus vancomycin in the patient subgroups over a period of 1 year from initial infection. Cost and outcome data used to parameterise the model were taken from Spanish sources and published literature. The costs were from the Spanish hospital perspective, in Euros (€) and for 2013. For CDI patients with cancer, fidaxomicin was dominant versus vancomycin [gain of 0.016 quality-adjusted life-years (QALYs) and savings of €2,397 per patient]. At a cost-effectiveness threshold of €30,000 per QALY gained, the probability that fidaxomicin was cost-effective was 96%. For CDI patients treated with concomitant antibiotic therapy, fidaxomicin was the dominant treatment versus vancomycin (gain of 0.014 QALYs and savings of €1,452 per patient), with a probability that fidaxomicin was cost-effective of 94%. For CDI patients with renal impairment, fidaxomicin was also dominant versus vancomycin (gain of 0.013 QALYs and savings of €1,432 per patient), with a probability that fidaxomicin was cost-effective of 96%. Over a 1-year time horizon, when fidaxomicin is compared to vancomycin in CDI patients with cancer, treated with concomitant antibiotic therapy or with renal impairment, the use of fidaxomicin would be expected to result in increased QALYs for patients and reduced overall costs. Springer-Verlag Berlin Heidelberg, 2015 Rubio-Terrés C. Health Value, C/-Virgen de Aránzazu, 21, 5°B, 28034, Madrid, Spain aut Cobo Reinoso J. Infectious Diseases Department, Hospital Universitario Ramón y Cajal, Madrid, Spain aut Grau Cerrato S. Pharmacy Department (IRYCIS), Hospital del Mar, Barcelona, Spain aut Mensa Pueyo J. Infectious Diseases Department, Hospital Clínic, Barcelona, Spain aut Salavert Lletí M. Infectious Diseases Unit, Hospital Universitario La Fe, Valencia, Spain aut Toledo A. Astellas Pharma, Madrid, Spain aut Anguita P. Astellas Pharma, Madrid, Spain aut Rubio-Rodríguez D. Health Value, C/-Virgen de Aránzazu, 21, 5°B, 28034, Madrid, Spain aut Watt M. Astellas Pharma EMEA, London, UK aut Gani R. Astellas Pharma EMEA, London, UK aut European Journal of Clinical Microbiology & Infectious Diseases Springer Berlin Heidelberg 34/11(2015-11-01), 2213-2223 0934-9723 34:11<2213 2015 34 10096 https://doi.org/10.1007/s10096-015-2472-0 text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s10096-015-2472-0 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Rubio-Terrés C. Health Value, C/-Virgen de Aránzazu, 21, 5°B, 28034, Madrid, Spain aut NATIONALLICENCE 700 1- Cobo Reinoso J. Infectious Diseases Department, Hospital Universitario Ramón y Cajal, Madrid, Spain aut NATIONALLICENCE 700 1- Grau Cerrato S. Pharmacy Department (IRYCIS), Hospital del Mar, Barcelona, Spain aut NATIONALLICENCE 700 1- Mensa Pueyo J. Infectious Diseases Department, Hospital Clínic, Barcelona, Spain aut NATIONALLICENCE 700 1- Salavert Lletí M. Infectious Diseases Unit, Hospital Universitario La Fe, Valencia, Spain aut NATIONALLICENCE 700 1- Toledo A. Astellas Pharma, Madrid, Spain aut NATIONALLICENCE 700 1- Anguita P. Astellas Pharma, Madrid, Spain aut NATIONALLICENCE 700 1- Rubio-Rodríguez D. Health Value, C/-Virgen de Aránzazu, 21, 5°B, 28034, Madrid, Spain aut NATIONALLICENCE 700 1- Watt M. Astellas Pharma EMEA, London, UK aut NATIONALLICENCE 700 1- Gani R. Astellas Pharma EMEA, London, UK aut NATIONALLICENCE 773 0- European Journal of Clinical Microbiology & Infectious Diseases Springer Berlin Heidelberg 34/11(2015-11-01), 2213-2223 0934-9723 34:11<2213 2015 34 10096